Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study

Pohar, K. S., Patel, S., Lotan, Y., Trabulsi, E., Woods, M., Downs, T., Huang, W. C., Jones, J., Taylor, J., O’Donnell, M., Bivalacqua, T. J., DeCastro, J., Steinberg, G., Kamat, A. M., Resnick, M. J., Konety, B., Schoenberg, M., Jones, J. S., & Daneshmand, S. (2022). Safety of repeat blue light cystoscopy with hexaminolevulinate (HAL) in the management of bladder cancer: Results from a phase III, comparative, multi-center study. Urologic Oncology: Seminars and Original Investigations, 40(8), 382.e1-382.e6. https://doi.org/10.1016/j.urolonc.2022.04.012
Authors:
Kamal S. Pohar
Sanjay Patel
Yair Lotan
Edouard Trabulsi
Michael Woods
Tracy Downs
William C. Huang
Jeffrey Jones
Jennifer Taylor
Michael O'Donnell
Trinity J. Bivalacqua
Joel DeCastro
Gary Steinberg
Ashish M. Kamat
Matthew J. Resnick
Badrinath Konety
Mark Schoenberg
J. Stephen Jones
Siamak Daneshmand
Affiliated Authors:
Joel DeCastro
Subjects:
Author Keywords:
bladder cancer
blue light cystoscopy
hal
hexaminolevulinate
safety
Publication Type:
Article
Unique ID:
10.1016/j.urolonc.2022.04.012
PMID:
Publication Date:
Data Source:
Scopus

Record Created: